"Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis" by Qing Liu

Article

Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis

Qing Liu
Karl E. Peace, Georgia Southern University

Link

Document Type

Article

Publication Date

4-21-2020

Disciplines

Biostatistics,
Environmental Public Health,
Epidemiology and
Public Health

Abstract

To supplement both the FDA and EMA guidance, we describe the principles and key elements for developing a DMC chart for individual clinical trials affected by COVID-19.

Citation Information

Qing Liu and Karl E. Peace. "Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis" LinkedIn (2020)
Available at: http://works.bepress.com/karl_peace/371/